Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 857 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 857 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total value of $73,359.20. Following the completion of the sale, the vice president now owns 23,890 shares in the company, valued at approximately $2,044,984. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $2.33 during trading on Thursday, reaching $87.42. The company had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. The firm has a market capitalization of $52.68 billion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The stock’s fifty day moving average price is $90.03 and its 200 day moving average price is $79.73. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Institutional Trading of Edwards Lifesciences

Large investors have recently bought and sold shares of the company. Nordea Investment Management AB grew its holdings in Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Telos Capital Management Inc. lifted its position in shares of Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after acquiring an additional 56,000 shares in the last quarter. Arlington Trust Co LLC lifted its position in shares of Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after acquiring an additional 12,069 shares in the last quarter. Versor Investments LP lifted its position in shares of Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after acquiring an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $1,587,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EW shares. Wells Fargo & Company upped their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Evercore ISI dropped their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. Morgan Stanley increased their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Citigroup increased their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Mizuho increased their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.27.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.